Initial multicentre experience of 68gallium‐PSMA PET/CT guided robot‐assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited

To evaluate the safety and short‐term oncological outcomes of 68gallium‐labelled prostate‐specific membrane antigen (68Ga‐PSMA) positron‐emission tomography (PET)/computed tomography (CT)‐directed robot‐assisted salvage node dissection (RASND) for prostate cancer oligometastatic nodal recurrence.

[1]  F. Montorsi,et al.  Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer. , 2017, European urology.

[2]  P. Stricker,et al.  Prospective evaluation of 68Gallium‐prostate‐specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer , 2017, BJU international.

[3]  T. Kuru,et al.  The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer , 2016, Prostate Cancer and Prostatic Diseases.

[4]  K. Pienta,et al.  Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations , 2017, Nature Reviews Urology.

[5]  Damien Bolton,et al.  Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. , 2016, European urology.

[6]  J. Yaxley,et al.  The use of 68 Ga‐PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer , 2016, BJU international.

[7]  M. Schwaiger,et al.  Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy , 2016, The Journal of Nuclear Medicine.

[8]  P. Stricker,et al.  68Ga‐PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment , 2016, BJU international.

[9]  R. Knuechel,et al.  Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with 68Ga-PSMA-HBED-CC than with 18F-Fluoroethylcholine PET/CT , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  B. Davis,et al.  Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy. , 2016, European urology.

[11]  S. Fanti,et al.  (68)Ga-PSMA-PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse After Radical Prostatectomy for Prostate Cancer. , 2015, Clinical genitourinary cancer.

[12]  C. Ritter,et al.  Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga‐PSMA‐positron emission tomography/computerized tomography , 2015, The Prostate.

[13]  S. Fanti,et al.  Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy , 2015, The Journal of Nuclear Medicine.

[14]  F. Montorsi,et al.  Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. , 2015, European urology.

[15]  M. Roach,et al.  Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. , 2015, European urology.

[16]  O. Yossepowitch.  Salvage lymph node dissection for biochemical recurrence following radical prostatectomy: is the evidence there? , 2015, European urology.

[17]  F. Montorsi,et al.  Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy. , 2015, European urology.

[18]  F. Montorsi,et al.  Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. , 2015, European urology.

[19]  N. Lumen,et al.  Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial , 2014, BMC Cancer.

[20]  P. Stricker,et al.  Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve: a prospective single-surgeon study of 1552 consecutive cases. , 2014, European urology.

[21]  N. Lumen,et al.  Prognostic factors influencing prostate cancer‐specific survival in non‐castrate patients with metastatic prostate cancer , 2014, The Prostate.

[22]  I. Tannock,et al.  The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. , 2014, European urology.

[23]  F. Wan,et al.  A systematic review and meta-analysis of comparative studies on the efficacy of extended pelvic lymph node dissection in patients with clinically localized prostatic carcinoma , 2014, Journal of Cancer Research and Clinical Oncology.

[24]  A. D'Amico,et al.  Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. , 2013, European urology.

[25]  T. Holland-Letz,et al.  Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  A. Salonia,et al.  Salvage lymphadenectomy in postprostatectomy patients with prostate-specific antigen recurrence , 2011, Current opinion in urology.

[27]  M. Cooperberg,et al.  Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. , 2010, European urology.

[28]  F. Montorsi,et al.  Pelvic lymph node dissection in prostate cancer. , 2009, European urology.

[29]  E. Klein,et al.  Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. , 2007, European urology.

[30]  A. Partin,et al.  Biochemical relapse after primary treatment for prostate cancer: studies on natural history and therapeutic considerations. , 2004, Journal of the National Comprehensive Cancer Network : JNCCN.

[31]  J. Sanabria,et al.  Proposed classification of complications of surgery with examples of utility in cholecystectomy. , 1992, Surgery.